DNMT1 and chronic myelomonocytic leukemia: At the same time, the most commonly employed treatment strategy for CMML is the inhibition of DNMT with DNA methyltransferase inhibitors (i.e. azacytidine ± cedazuridine, decitabine), which are thought to epigenetically restore normal hematopoiesis in a subset of patients without altering the mutational burden or inherent risk of leukemic transformation42–44.